Literature DB >> 1548250

Methylphenidate and seizure frequency in brain injured patients with seizure disorders.

B A Wroblewski1, J M Leary, A M Phelan, J Whyte, K Manning.   

Abstract

BACKGROUND: Psychostimulant drugs such as methylphenidate are increasingly being used in patients with traumatic brain injury or other brain injuries for a variety of cognitive and behavioral problems. However, there is some reluctance among clinicians and family members to use methylphenidate in brain injured patients because of warnings of seizure occurrence, which are prominently reported by the product labeling included in the Physicians' Desk Reference.
METHOD: We retrospectively studied the use of methylphenidate in 30 consecutive patients with active seizure disorders. We compared the seizure frequency in the 3 months before and after methylphenidate with the seizure frequency during methylphenidate treatment, using the Wilcoxon signed-rank test.
RESULTS: Overall, the findings demonstrated a trend toward a lesser incidence of seizures in patients during methylphenidate treatment. Only 4 patients had greater seizure frequency during methylphenidate treatment, and 3 of these 4 were receiving tricyclic antidepressants.
CONCLUSION: Methylphenidate can be safely used in brain injured patients, even those at high risk for seizures, as it was associated with a trend toward reduction (rather than increase) in seizure frequency in this population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548250

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  20 in total

1.  Evaluation and Management of Posttraumatic Cognitive Impairments.

Authors:  David B Arciniegas; Kimberly L Frey; Jody Newman; Hal S Wortzel
Journal:  Psychiatr Ann       Date:  2010-11-01

Review 2.  Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.

Authors:  M Tan; R Appleton
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

Review 3.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

Review 4.  Attention deficit hyperactivity disorder--a review.

Authors:  C Williams; B Wright; I Partridge
Journal:  Br J Gen Pract       Date:  1999-07       Impact factor: 5.386

5.  Cognitive Impairment Following Traumatic Brain Injury.

Authors:  David B. Arciniegas; Kerri Held; Peter Wagner
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

Review 6.  Management of psychiatric and neurological comorbidities in epilepsy.

Authors:  Andres M Kanner
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

Review 7.  Extended-release methylphenidate (Ritalin LA).

Authors:  Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors:  B H Smith; D A Waschbusch; M T Willoughby; S Evans
Journal:  Clin Child Fam Psychol Rev       Date:  2000-12

Review 9.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

10.  Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.

Authors:  Isabell Brikell; Qi Chen; Ralf Kuja-Halkola; Brian M D'Onofrio; Kelsey K Wiggs; Paul Lichtenstein; Catarina Almqvist; Patrick D Quinn; Zheng Chang; Henrik Larsson
Journal:  Epilepsia       Date:  2019-01-25       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.